Close Menu

bevacizumab

A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.

The researchers said their findings could explain improved outcomes of sarcomatoid tumors to checkpoint blockade versus antiangiogenic therapies alone.

HalioDx's Immunoscore test, which measures host immune response at the tumor site, will be used to select patients for the trial.